Abstract: There are numerous surgical approaches for the treatment of pericardial effusions but no clear consensus of best management. We present a 44-year-old woman with metastatic breast cancer presenting with a new 2-cm pericardial effusion on ultrasound. In light of the patient's palliative condition and the urgent need for chemotherapy, careful consideration was made for her surgical drainage of the pericardial effusion. Because of the patient's medical comorbidities, a general anesthetic was deemed not to be in the patient's best interest. Furthermore, the invasive subxiphoid or thoracotomy approach for a pericardial window would have risked delaying her much needed chemotherapy. A single-port thoracoscopic pericardial window was performed under light sedation, ventilating spontaneously on supplementary oxygen through nasal cannula only. The patient was positioned in a supine position, and a single 8-mm port was inserted into the left hemithorax at the 5th intercostal space, midaxillary line under local anesthetic, and a pericardial window made. This minimally invasive approach, without the need for intubation or ventilation, allowed for rapid relief of symptoms and discharge for the patient to begin her chemotherapy in a timely manner. By undergoing the procedure awake and through a single port, the patient was discharged after a short inpatient stay. This novel approach can be advocated for patients where a general anesthetic or invasive surgical procedure is not suitable in the treatment of their pericardial effusion.
T he pericardium is a thin fibroelastic sac that encloses the heart and separates it from the mediastinum. While normally there is approximately 50 mL of fluid within the pericardium, a pericardial effusion is a pathological collection of fluid within this sac. 1 The accumulation of fluid can be either acute or chronic, with up to 2 liters of fluid accumulating in the latter. Effusions are categorized as small, medium, or large, depending on the volume, localization, and maximal width. Causes of pericardial effusions are classified as either exudative or transudative. Exudative causes include malignancy, inflammatory causes such a rheumatoid arthritis, systemic lupus erythematosus, and sarcoidosis and rarer causes such as infection. Transudative causes in turn include metabolic disorders such as hypothyroidism and uremia, trauma, and radiation. [2] [3] [4] Pericardial effusions can present as either asymptomatic or symptomatic associated with inflammation and extrinsic compression. Cardiac tamponade can occur with fluid accumulation in the finite pericardial space causing an increase in pressure, reduced venous return and hemodynamic compromise with classic signs of increased heart rate and Beck triad of venous congestion, hypotension, and muffled heart sounds. Cardiac tamponade has been recorded in 25% to 30% of patients with a large pericardial effusion and is a medical emergency requiring urgent management. 4 Echocardiography remains the main investigation in the diagnosis of pericardial effusion and allows the sizing of effusion as defined previously. 1 Computer tomography and magnetic resonance imaging can also be used in the event of a nondiagnostic echocardiogram and is especially helpful in small effusions.
The treatment of an effusion is based on the underlying cause. Effusions showing signs of tamponade regardless of cause however require immediate drainage by pericardiocentesis.
The surgical management of effusion is a pericardial window, and this can be performed via a subxiphoid, thoracotomy, or visually assisted thoracoscopic approach. The subxiphoid and thoracoscopic approaches are generally advocated and well tolerated by patients with comparable postoperative complications rates and length of stay. 5, 6 The subxiphoid approach compared with a thoracotomy is associated with less postoperative pain and quicker extubation and provides a safe and simple method in those with malignancy and palliative aims.
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CASE REPORT
A 44-year-old woman was referred to a cardiothoracic center with a history of grade 3 node positive invasive ductal carcinoma. This was previously treated in 2012 with a left mastectomy and axillary node clearance and further neoadjuvant chemoradiotherapy with fluorouracil, epirubicin, cyclophosphamide and docetaxel (Taxotere) as she was human epidermal growth factor receptor 2 positive. In 2016, she presented with new symptoms of hoarse voice and neck discomfort and was found to have a new vocal cord palsy and bilateral cervical lymph node enlargement.
Subsequent computed tomography imaging confirmed a new 6.3 Â 3.8-cm mediastinal mass with enlargement of subcarinal lymph nodes, narrowing of the trachea, and evidence of metastasis to the spleen. The computed tomography also demonstrated a moderate pericardial effusion confirmed on echocardiography measuring 2 cm posterolaterally and 1.2 cm anteriorly.
On clinical assessment, the patient was hemodynamically stable with no evidence of cardiac tamponade; however, she required drainage of the effusion for symptom relief. The subsequent oncological plan was for further combination chemotherapy.
In light of the patient's palliative condition and the urgent need for chemotherapy, careful consideration was made for her surgical drainage of the pericardial effusion. A general anesthetic and the subsequent recovery from either a subxiphoid or thoracotomy had a high risk of delaying her much needed chemotherapy.
A single-port thoracoscopic pericardial window was therefore performed under light sedation, ventilating spontaneously on supplementary oxygen through nasal cannula only. The patient was positioned in a supine position, and a single 8-mm port was inserted into the left hemithorax at the 5th intercostal space, midaxillary line (Fig. 1) . Local anesthetic of bupivacaine was administered to the site of the port only. Under direct visualization, a ring diathermy was used to make a pericardial window to decompress the effusion. Through the same port, a pericardial biopsy was also taken (Fig. 2) . Hemostasis was achieved with no intraoperative complications. A single 28F chest drain was inserted into the position of the thoracoscopic port, chosen in light of the pleural perforation from the thoracoscopic approach.
The patient tolerated the procedure well with minimal pain experienced. She was transferred directly to the ward and remained well. The drain was removed less than 48 hours later and discharged home on the same day of drain removal to begin her chemotherapy at her referring trust with the biopsy results, demonstrating a recurrence of the primary from 2012.
Although nonintubated thoracic surgery has been widely, we believe that this is the first case in the literature that a pericardial window was conducted thoracoscopically through a single port under local anesthetic only.
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CONCLUSIONS
In patients with such advanced disease and poor prognosis, the anesthetic and postoperative complications of a standard thoracotomy, subxiphoid, or thoracoscopic pericardial window are unacceptable. In this patient, any subsequent complication would potentially delay her chemotherapy that would be key in her treatment.
By undergoing the procedure awake and through a single port, she was able to be discharged with a short inpatient stay while minimizing chances of anesthetic related complications, for a symptom-relieving procedure, allowing her to begin her course of chemotherapy.
We the authors feel that this minimally invasive thoracoscopic surgery for an awake patient provides both a diagnostic and therapeutic option in a specific group of patients. The benefits of minimizing the postoperative recovery from a single port and avoiding the added risks of a general anesthetic need to be carefully weighed up against the increased intraoperative technical challenges faced by such a minimally invasive approach but also the increased risks of an unanesthetized patient in the event of any postoperative complications. However, with careful consideration of risk versus benefit as shown in this case report in a select group of patients, this approach can be used with good clinical outcomes. 
